HER2 human epidermal growth factor receptor

Note IL2, interluekin 2 HER2, human epidermal growth factor receptor 2 RSV, respiratory syncytial virus TNF, tumor necrosis factor IgE, Immunoglobulin E EGER, epidermal growth factor receptor VEGF, vascular endothelial growth factor. 

HER2 human epidermal growth factor receptor-2... 

Abbreviations NAT2, N-acetyltransferase 2 TPMT, thiopurine S-methyltransferase UGT1A1, UDP-glucuronosyltransferase 1A1 HER2, human epidermal growth factor receptor 2 (ErbB2) EICV, hepatitis C virus TCAs, tricyclic antidepressants ADRs, adverse drug reactions. 

HER2 human epidermal growth factor receptor. Also known as Neu, ErB-2, CD340, or pi 85... 

Receptor HCG Human chorionogonadotropic hormone HER2 Human Epidermal Growth Factor Receptor-2 ICAM-1 Intracellular adhesion molecule-1 LAGS ... 

Figure 7.3 The ER 1D5 peptide only binds to the ER 1D5 mAb (upper left and lower right). Other mAbs do not bind. The antibody abbreviations in the lower panel are Her2 11G5, and 9C2, human epidermal growth factor receptor type 2 clones 11G5 and 9C2 Mela-HMB45, melanocyte-specific antibody clone HMB45 Vimen V9, vimentin clone V9 Anti-LCA, anti-leukocyte common antigen clones PD7/26 and 2B11, combined as a cocktail Mouse poly IgG, mouse polyclonal IgG. Reproduced with permission from Sompuram et al.7...

Trastuzumab is licensed for the treatment of early breast cancer that overexpresses human epidermal growth factor receptor-2 (HER2). It may be administered as monotherapy or in combination with, for example, paclitaxel, docetaxel (taxanes) or anastrozole (aromatase inhibitors). Since trastuzumab can cause cardiotoxicity, concomitant use with anthracyclines such as... 

Van de Vijver, M. J. 2001. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur. J. Cancer 37 511-517. 

Fendly, B. M., Winget, M., Hudziak, R. M., Lipari, M. T., Napier, M. A., and Ullrich, A. (1990). Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50,1550-1558. 

First-line treatment of her metastatic breast cancer should therefore incorporate the monoclonal antibody trastuzumab (Herceptin). NICE (2002b) have issued a technology appraisal on the use of trastuzumab in metastatic breast cancer which states that trastuzumab be used in combination with paclitaxel for women with tumours with excessive human epidermal growth factor receptor 2 (HER2) at levels of 3+ who have not had chemotherapy for metastatic breast cancer and for whom anthracycline treatment is inappropriate. ... 

Herceptin is the trade name given to one such antibody-based cancer therapy product (Table 8). It is a humanized niAb with binding specificity for the human epidermal growth factor receptor 2 (HER2), which is overexpressed on the surface of 25-30% of metastatic breast cancers. HER2 overexpression induces abnormal proliferation of cells (see also Part I, Chapter 5). The niAb binds specifically to the... 

Hendriks BS, Opresko LK, Wiley HS, et al. Coregulation of epidermal growth factor re-ceptor/human epidermal growth factor receptor 2 (HER2) levels and locations quantitative analysis of HER2 overexpression effects. Cancer Res 2003, 63, 1130-1137. 

A monoclonal antibody against human epidermal growth factor receptors (HER2) has been developed for use in metastatic breast cancer. This dmg is trastuzumab (Herceptin) and is also being monitored by the MHRA. 

---